Radius Health Company Profile (NASDAQ:RDUS)

About Radius Health (NASDAQ:RDUS)

Radius Health logoRadius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company's clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RDUS
  • CUSIP: N/A
  • Web: www.radiuspharm.com
Capitalization:
  • Market Cap: $1.88128 billion
  • Outstanding Shares: 43,377,000
Average Prices:
  • 50 Day Moving Avg: $43.82
  • 200 Day Moving Avg: $40.67
  • 52 Week Range: $31.58 - $59.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.07
  • P/E Growth: -3.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $6.06 per share
  • Price / Book: 6.78
Profitability:
  • EBIDTA: ($200,700,000.00)
  • Return on Equity: -60.78%
  • Return on Assets: -56.01%
Debt:
  • Current Ratio: 8.75%
  • Quick Ratio: 8.75%
Misc:
  • Average Volume: 1.26 million shs.
  • Beta: 1.36
  • Short Ratio: 10.54
 
Frequently Asked Questions for Radius Health (NASDAQ:RDUS)

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health, Inc. (NASDAQ:RDUS) posted its quarterly earnings results on Thursday, May, 4th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.18) by $0.14. During the same period in the previous year, the business posted ($0.94) EPS. View Radius Health's Earnings History.

Where is Radius Health's stock going? Where will Radius Health's stock price be in 2017?

7 analysts have issued 12 month price objectives for Radius Health's stock. Their predictions range from $24.00 to $85.00. On average, they anticipate Radius Health's share price to reach $55.67 in the next twelve months. View Analyst Ratings for Radius Health.

What are analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:

  • 1. According to Zacks Investment Research, "Although the FDA’s approval of Radius Health’s lead drug, Tymlos, is a significant boost for the company, expenses continues to rise. Although the osteoporosis market in the U.S. has great potential as approximately 1.4 million postmenopausal women in the U.S. experience an osteoporotic fracture each year, Tymlos is expected to face significant competition from Eli Lilly & Co's Forteo and Amgen Inc's Prolia. Moreover, the approved label carries a boxed warning of osteosarcoma (a malignant bone tumor). Hence, we expect investors to focus on the drug’s pricing and uptake post launch. Although we are pleased with Radius' efforts in developing its pipeline, we note that most of its candidates are in their early or mid stages of development. Meanwhile, the company’ shares have outperformed the Zacks classified Medical-Drugs industry in the last six months." (7/4/2017)
  • 2. Canaccord Genuity analysts commented, "Date and time of first dissemination: April 28, 2017, 11:13 ET Date and time of production: April 28, 2017, 11:13 ET Target Price / Valuation Methodology: Radius Health – RDUS Our $85 price target is based on a probability adjusted EV/S methodology." (4/28/2017)
  • 3. Cantor Fitzgerald analysts commented, "RDUS shares are rallying this morning (+2%) on FDA approval of TYMLOS (abaloparatide-SC) ahead of expectations, as the extended PDUFA was June." (4/28/2017)

Who are some of Radius Health's key competitors?

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:

  • Kurt C. Graves, Independent Chairman of the Board
  • Jesper Hoiland, President, Chief Executive Officer, Director
  • Jose Carmona, Chief Financial Officer, Principal Accounting Officer, Treasurer
  • Gary Hattersley Ph.D., Senior Vice President, Chief Scientific Officer
  • Brent Hatzis-Schoch, Senior Vice President, General Counsel, Secretary
  • Lorraine A. Fitzpatrick M.D., Chief Medical Officer
  • David P. Snow, Chief Commercial Officer
  • Gregory Williams Ph.D., Chief Development Officer
  • Alan H. Auerbach, Independent Director
  • Willard H. Dere M.D., Independent Director

Who owns Radius Health stock?

Radius Health's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Creative Planning (0.07%), Hamilton Lane Advisors LLC (0.04%), Russell Investments Group Ltd. (0.03%), Verde Servicos Internacionais S.A. (0.03%), Salzhauer Michael (0.02%) and Public Employees Retirement Association of Colorado (0.02%). Company insiders that own Radius Health stock include Gary Hattersley, Growth N V Biotech, Kurt Graves and Rob Ward. View Institutional Ownership Trends for Radius Health.

Who sold Radius Health stock? Who is selling Radius Health stock?

Radius Health's stock was sold by a variety of institutional investors in the last quarter, including Verde Servicos Internacionais S.A. and Carl Domino Inc. View Insider Buying and Selling for Radius Health.

Who bought Radius Health stock? Who is buying Radius Health stock?

Radius Health's stock was bought by a variety of institutional investors in the last quarter, including Creative Planning and Russell Investments Group Ltd.. View Insider Buying and Selling for Radius Health.

How do I buy Radius Health stock?

Shares of Radius Health can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of Radius Health stock can currently be purchased for approximately $41.07.


MarketBeat Community Rating for Radius Health (NASDAQ RDUS)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  231 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  333
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Radius Health (NASDAQ:RDUS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $55.67 (35.54% upside)

Analysts' Ratings History for Radius Health (NASDAQ:RDUS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/23/2017Cantor FitzgeraldSet Price TargetBuy$58.00MediumView Rating Details
7/17/2017Canaccord GenuitySet Price TargetBuy$85.00HighView Rating Details
6/5/2017Jefferies Group LLCSet Price TargetHold$34.00LowView Rating Details
5/24/2017Maxim GroupSet Price TargetSell$24.00LowView Rating Details
5/15/2017HC WainwrightReiterated RatingBuy$63.00LowView Rating Details
5/2/2017Cowen and CompanyDowngradeOutperform -> Market PerformLowView Rating Details
3/11/2017J P Morgan Chase & CoReiterated RatingBuyMediumView Rating Details
3/30/2016Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$37.00N/AView Rating Details
1/25/2016Bank of America CorporationReiterated RatingBuy$89.00N/AView Rating Details
8/14/2015Deutsche Bank AGInitiated CoverageBuy$90.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Radius Health (NASDAQ:RDUS)
Earnings by Quarter for Radius Health (NASDAQ:RDUS)
Earnings History by Quarter for Radius Health (NASDAQ RDUS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($1.18)($1.32)ViewListenView Earnings Details
2/23/2017Q416($1.34)($1.22)ViewN/AView Earnings Details
11/3/2016Q316($1.03)($1.07)$0.75 millionViewN/AView Earnings Details
8/4/2016Q216($0.95)($1.01)ViewN/AView Earnings Details
5/5/2016Q116($0.74)($0.94)ViewN/AView Earnings Details
2/25/2016Q415($0.64)($0.77)ViewListenView Earnings Details
11/5/2015Q315($0.58)($0.68)ViewN/AView Earnings Details
8/6/2015Q215($0.52)($0.61)ViewN/AView Earnings Details
5/6/2015Q115($0.52)($0.47)ViewN/AView Earnings Details
3/10/2015Q414($0.63)($0.55)ViewN/AView Earnings Details
11/10/2014Q314($0.65)($0.59)ViewN/AView Earnings Details
8/12/2014Q2($0.89)($2.22)$16.24 million$10.62 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Radius Health (NASDAQ:RDUS)
2017 EPS Consensus Estimate: ($4.82)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.94)($0.94)($0.94)
Q2 20171($1.37)($1.37)($1.37)
Q3 20171($1.31)($1.31)($1.31)
Q4 20171($1.20)($1.20)($1.20)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Radius Health (NASDAQ:RDUS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Radius Health (NASDAQ:RDUS)
Insider Ownership Percentage: 15.00%
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)
Insider Trades by Quarter for Radius Health (NASDAQ:RDUS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017Growth N V BiotechMajor ShareholderBuy40,000$34.21$1,368,400.00View SEC Filing  
5/25/2017Growth N V BiotechMajor ShareholderBuy40,000$36.25$1,450,000.00View SEC Filing  
5/18/2017Growth N V BiotechMajor ShareholderBuy50,000$34.41$1,720,500.00View SEC Filing  
5/17/2017Growth N V BiotechMajor ShareholderBuy35,000$33.44$1,170,400.00View SEC Filing  
5/12/2017Growth N V BiotechMajor ShareholderBuy15,000$34.00$510,000.00View SEC Filing  
5/9/2017Growth N V BiotechMajor ShareholderBuy50,000$35.93$1,796,500.00View SEC Filing  
5/8/2017Growth N V BiotechMajor ShareholderBuy43,400$35.57$1,543,738.00View SEC Filing  
5/2/2017Growth N V BiotechMajor ShareholderBuy75,000$33.91$2,543,250.00View SEC Filing  
5/1/2017Growth N V BiotechMajor ShareholderBuy150,000$35.39$5,308,500.00View SEC Filing  
3/21/2017Growth N V BiotechMajor ShareholderBuy50,000$35.83$1,791,500.00View SEC Filing  
3/17/2017Growth N V BiotechMajor ShareholderBuy30,000$38.41$1,152,300.00View SEC Filing  
3/15/2017Growth N V BiotechMajor ShareholderBuy61,721$39.97$2,466,988.37View SEC Filing  
3/10/2017Growth N V BiotechMajor ShareholderBuy38,279$39.17$1,499,388.43View SEC Filing  
1/22/2016Growth N V BiotechMajor ShareholderBuy38,259$31.67$1,211,662.53View SEC Filing  
1/13/2016Growth N V BiotechMajor ShareholderBuy50,000$39.90$1,995,000.00View SEC Filing  
11/12/2015Gary HattersleyinsiderSell5,683$75.00$426,225.00View SEC Filing  
11/3/2015Gary HattersleyinsiderSell13,333$70.00$933,310.00View SEC Filing  
10/23/2015Gary HattersleyinsiderSell11,302$65.00$734,630.00View SEC Filing  
10/21/2015Gary HattersleyinsiderSell1,501$65.36$98,105.36View SEC Filing  
10/21/2015Rob WardCEOSell50,000$61.99$3,099,500.00View SEC Filing  
8/21/2015Growth N. V. Biotechmajor shareholderBuy100,000$64.00$6,400,000.00View SEC Filing  
8/17/2015Kurt GravesDirectorSell22,694$70.00$1,588,580.00View SEC Filing  
7/6/2015Kurt GravesDirectorSell25,000$69.48$1,737,000.00View SEC Filing  
6/18/2015Kurt GravesDirectorSell25,000$55.05$1,376,250.00View SEC Filing  
5/1/2015Growth N V BiotechMajor ShareholderBuy50,000$36.46$1,823,000.00View SEC Filing  
4/29/2015Growth N V BiotechMajor ShareholderBuy50,000$36.23$1,811,500.00View SEC Filing  
4/28/2015Growth N V BiotechMajor ShareholderBuy50,000$36.59$1,829,500.00View SEC Filing  
4/27/2015Growth N V BiotechMajor ShareholderBuy50,000$38.38$1,919,000.00View SEC Filing  
3/6/2015Growth N V BiotechMajor ShareholderBuy75,000$47.08$3,531,000.00View SEC Filing  
2/25/2015Growth N V BiotechMajor ShareholderBuy35,000$45.74$1,600,900.00View SEC Filing  
6/11/2014Morana Jovan-EmbiricosDirectorBuy587,500$8.00$4,700,000.00View SEC Filing  
6/6/2014Growth N V BiotechMajor ShareholderBuy1,000,000$8.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Radius Health (NASDAQ:RDUS)
Latest Headlines for Radius Health (NASDAQ:RDUS)
Source:
DateHeadline
americanbankingnews.com logoRadius Health, Inc. (RDUS) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 10:49 AM
americanbankingnews.com logoJefferies Group Comments on Radius Health, Inc.'s Q3 2017 Earnings (RDUS)
www.americanbankingnews.com - July 26 at 9:48 AM
finance.yahoo.com logoWill Radius Health (RDUS) Disappoint this Earnings Season?
finance.yahoo.com - July 26 at 6:42 AM
benzinga.com logoApparently Fake Press Release Roils Radius Health Investors - Benzinga
www.benzinga.com - July 23 at 7:30 AM
streetinsider.com logoRadius Health (RDUS) Announces CHMP Has Issued Second Day-180 List of Outstanding Issues in Regulatory ... - StreetInsider.com
www.streetinsider.com - July 22 at 8:11 AM
americanbankingnews.com logo Brokerages Anticipate Radius Health, Inc. (NASDAQ:RDUS) Will Post Earnings of -$1.35 Per Share
www.americanbankingnews.com - July 19 at 2:44 PM
americanbankingnews.com logoHead-To-Head Analysis: Intercept Pharmaceuticals (ICPT) vs. Radius Health (RDUS)
www.americanbankingnews.com - July 19 at 8:51 AM
streetinsider.com logoRadius Health (RDUS) Names Jesper Hoiland as President and CEO - StreetInsider.com
www.streetinsider.com - July 18 at 7:46 AM
investorplace.com logoWhy Tesla Inc (TSLA), Radius Health Inc (RDUS) and Blue Apron ... - Investorplace.com
investorplace.com - July 18 at 7:46 AM
streetinsider.com logoRadius Health (RDUS) Announces Pact for Abaloparatide-SC with Teijin Limited in Japan - StreetInsider.com
www.streetinsider.com - July 13 at 8:20 PM
streetinsider.com logoRadius Health (RDUS) Announces Pact for Abaloparatide-SC with Teijin Limited in Japan
www.streetinsider.com - July 13 at 8:33 AM
finance.yahoo.com logoRadius Health Announces License and Development Agreement for Abaloparatide-SC with Teijin Limited in Japan
finance.yahoo.com - July 13 at 8:33 AM
americanbankingnews.com logoZacks Investment Research Downgrades Radius Health, Inc. (NASDAQ:RDUS) to Sell
www.americanbankingnews.com - July 4 at 1:04 PM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - July 3 at 11:24 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 27 at 8:22 PM
americanbankingnews.com logo$1.96 Million in Sales Expected for Radius Health, Inc. (RDUS) This Quarter
www.americanbankingnews.com - June 25 at 9:44 AM
americanbankingnews.com logoRadius Health, Inc. (RDUS) Upgraded at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM
americanbankingnews.com logo-$1.35 Earnings Per Share Expected for Radius Health, Inc. (RDUS) This Quarter
www.americanbankingnews.com - June 23 at 12:17 PM
nasdaq.com logoRadius Health (RDUS) Shares Cross Above 200 DMA
www.nasdaq.com - June 21 at 3:29 AM
fool.com logoHere's Why Radius Health Inc. Stock Is Jumping Today - Motley Fool
www.fool.com - June 6 at 8:56 PM
finance.yahoo.com logoRadius Health (RDUS) Looks Good: Stock Adds 10.5% in Session
finance.yahoo.com - June 6 at 8:56 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 6 at 8:42 AM
americanbankingnews.com logoRadius Health Inc (RDUS) PT Set at $65.00 by Cantor Fitzgerald
www.americanbankingnews.com - June 5 at 10:34 PM
streetinsider.com logoRadius Health (RDUS) Delivers Positive Data From A Fully Enrolled Ongoing ...
www.streetinsider.com - June 5 at 8:08 PM
finance.yahoo.com logoHere's Why Radius Health Inc. Stock Is Jumping Today
finance.yahoo.com - June 5 at 8:08 PM
fool.com logoHere's Why Radius Health Inc. Stock Is Jumping Today
www.fool.com - June 5 at 4:50 PM
americanbankingnews.com logoJefferies Group LLC Reiterates "$34.00" Price Target for Radius Health Inc (RDUS)
www.americanbankingnews.com - June 5 at 2:26 PM
finance.yahoo.com logoCramer's lightning round: I'm blessing this chipmaker for a quick trade
finance.yahoo.com - June 4 at 7:39 PM
nasdaq.com logoRadius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug
www.nasdaq.com - June 4 at 9:23 AM
finance.yahoo.com logoRadius Presents Positive Data From A Fully Enrolled Ongoing Phase I Study for Investigational Drug Elacestrant (RAD1901) at the 2017 American Society of Clinical Oncology Annual Meeting (ASCO)
finance.yahoo.com - June 4 at 9:23 AM
nasdaq.com logoWhy Is Radius Health (RDUS) Down 2.7% Since the Last Earnings Report? - Nasdaq
www.nasdaq.com - June 3 at 6:55 PM
finance.yahoo.com logoWhy Is Radius Health (RDUS) Down 2.7% Since the Last Earnings Report?
finance.yahoo.com - June 1 at 9:06 PM
americanbankingnews.com logo$1.96 Million in Sales Expected for Radius Health Inc (RDUS) This Quarter
www.americanbankingnews.com - June 1 at 12:02 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Major Shareholder Buys $1,368,400.00 in Stock
www.americanbankingnews.com - May 31 at 4:26 PM
americanbankingnews.com logoGrowth N. V. Biotech Purchases 40,000 Shares of Radius Health Inc (RDUS) Stock
www.americanbankingnews.com - May 30 at 4:48 PM
americanbankingnews.com logo Analysts Expect Radius Health Inc (RDUS) Will Announce Earnings of -$1.35 Per Share
www.americanbankingnews.com - May 30 at 8:30 AM
americanbankingnews.com logoHC Wainwright Reiterates Buy Rating for Radius Health Inc (RDUS)
www.americanbankingnews.com - May 29 at 8:18 AM
americanbankingnews.com logoShort Interest in Radius Health Inc (RDUS) Grows By 26.7%
www.americanbankingnews.com - May 26 at 7:14 AM
americanbankingnews.com logoRadius Health Inc (RDUS) Given a $24.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - May 25 at 4:56 PM
streetinsider.com logoRadius Health (RDUS) Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS
www.streetinsider.com - May 24 at 7:52 PM
rttnews.com logoRadius Health Inc. (RDUS) Is Rising On Study Results
www.rttnews.com - May 24 at 7:52 PM
finance.yahoo.com logoRadius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis
finance.yahoo.com - May 24 at 7:52 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Given a $65.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 23 at 8:04 PM
seekingalpha.com logoRadius Health (RDUS) Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow
seekingalpha.com - May 23 at 9:40 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Radius Health and Biocept Inc.
finance.yahoo.com - May 23 at 9:40 AM
finance.yahoo.com logoBiotech Movers: Radius Health, Amgen, Paratek
finance.yahoo.com - May 22 at 6:36 PM
finance.yahoo.com logoAmgen Can Shrug Off Its Bone-Drug Risks
finance.yahoo.com - May 22 at 6:36 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Major Shareholder Growth N. V. Biotech Acquires 50,000 Shares
www.americanbankingnews.com - May 22 at 4:29 PM
americanbankingnews.com logoRadius Health Inc (RDUS) Stock Rating Reaffirmed by Canaccord Genuity
www.americanbankingnews.com - May 22 at 12:44 PM
americanbankingnews.com logoInsider Buying: Radius Health Inc (RDUS) Major Shareholder Buys 35,000 Shares of Stock
www.americanbankingnews.com - May 18 at 1:15 PM

Social

Chart

Radius Health (RDUS) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff